Schumann, Sarah http://orcid.org/0000-0003-4303-7068
Scherthan, Harry
Lapa, Constantin
Serfling, Sebastian
Muhtadi, Razan
Lassmann, Michael
Eberlein, Uta
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (LA 2304/3-2, SCHE 350/12-2)
Article History
Received: 23 November 2018
Accepted: 22 March 2019
First Online: 27 April 2019
Compliance with ethical standards
:
: Michael Lassmann has received research grants from Siemens Healthcare, Ipsen Pharma, Nordic Nanovector, ABX advanced biochemical compounds and is a member of the board of the EANM. Uta Eberlein is member of the EANM Dosimetry Committee. The other authors declare that they have no conflicts of interest.
: The research plan was presented to the Ethics Committee of the Medical Faculty of the University of Würzburg, Germany (Az: 209/14). The Ethics Committee approved the study stating that there were no objections to the conduct of the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Medical Faculty of the University of Würzburg and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.